Many of the cancers it covers lack standard screening protocols, making early detection difficult.
CancerSpot provides a non-invasive, accessible solution, enabling early identification and timely medical intervention when treatment outcomes are most effective.
Achieves high accuracy, with 72% sensitivity at 99% specificity on 14 cancer types.
Detects early cancer signals, demonstrating 70% sensitivity (at 99% specificity) for stage I cancers across 14 cancer types.
A simple blood test, that needs 20 ml of blood, and no ionizing radiation or cumbersome invasive procedures.
Covers 14 of the common cancers: Lung,Esophagus, Breast,Colorectal,Stomach,Liver, Pancreas,Gall Bladder,Ovary, Cervix,Prostate,Urinary bladder, Kidney,Uterus.
Detects cancer signatures consistently across ethnicities.
Lung, Esophagus, Breast, Colorectal,Stomach, Liver, Pancreas, Gall Bladder, Ovary, Cervix, Prostate, Urinary bladder, Kidney, Uterus
Find out through a one-on-one genetic counselling session.
Strand Life Sciences is India’s pioneering genomics company with over 25 years of research and is a Reliance portfolio company.
Yes. The test screens for genetic changes associated with early-stage cancers, helping you take preventive action before symptoms develop.
Anyone interested in proactive cancer prevention, especially those with a family history of cancer or planning for long-term health.
Your genetic counsellor will guide you on follow-up screenings, lifestyle adjustments, and preventive strategies tailored to your risk profile.
With Next-Generation Sequencing and CAP/NABL/ISO accreditation, the test provides highly accurate detection of relevant genetic markers.
CancerSpot is a screening test, not a diagnostic tool.
It cannot confirm or rule out cancer presence with complete certainty. A positive signal indicates the need for further diagnostic follow-up as advised by your physician.
₹24,000.00 Original price was: ₹24,000.00.₹18,000.00Current price is: ₹18,000.00.
₹7,500.00